🎉 M&A multiples are live!
Check it out!

Revvity Valuation Multiples

Discover revenue and EBITDA valuation multiples for Revvity and similar public comparables like Bangkok Dusit Medical Services, Integral Diagnostics, and Healius.

Revvity Overview

About Revvity

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.


Founded

1947

HQ

United States of America
Employees

11K+

Website

revvity.com

Financials

LTM Revenue $2.8B

LTM EBITDA $862M

EV

$13.9B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Revvity Financials

Revvity has a last 12-month revenue of $2.8B and a last 12-month EBITDA of $862M.

In the most recent fiscal year, Revvity achieved revenue of $2.8B and an EBITDA of $840M.

Revvity expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Revvity valuation multiples based on analyst estimates

Revvity P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $2.8B $2.8B XXX XXX XXX
Gross Profit $2.0B $1.5B XXX XXX XXX
Gross Margin 72% 56% XXX XXX XXX
EBITDA $714M $840M XXX XXX XXX
EBITDA Margin 26% 30% XXX XXX XXX
Net Profit $569M $693M XXX XXX XXX
Net Margin 21% 25% XXX XXX XXX
Net Debt $3.9B $3.0B XXX XXX XXX

Financial data powered by Morningstar, Inc.

Revvity Stock Performance

As of April 15, 2025, Revvity's stock price is $98.

Revvity has current market cap of $11.7B, and EV of $13.9B.

See Revvity trading valuation data

Revvity Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$13.9B $11.7B XXX XXX XXX XXX $4.91

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Revvity Valuation Multiples

As of April 15, 2025, Revvity has market cap of $11.7B and EV of $13.9B.

Revvity's trades at 5.0x LTM EV/Revenue multiple, and 16.1x LTM EBITDA.

Analysts estimate Revvity's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Revvity and 10K+ public comps

Revvity Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $13.9B XXX XXX XXX
EV/Revenue 5.0x XXX XXX XXX
EV/EBITDA 16.5x XXX XXX XXX
P/E 43.4x XXX XXX XXX
P/E/Growth 0.8x XXX XXX XXX
EV/FCF 25.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Revvity Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Revvity Valuation Multiples

Revvity's NTM/LTM revenue growth is 4%

Revvity's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Revvity's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Revvity's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Revvity and other 10K+ public comps

Revvity Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 0% XXX XXX XXX XXX
EBITDA Margin 30% XXX XXX XXX XXX
EBITDA Growth 18% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 34% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 7% XXX XXX XXX XXX
Opex to Revenue 43% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Revvity Public Comps

See public comps and valuation multiples for Laboratory Services and Medical Imaging & Diagnostics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Australian Clinical Labs XXX XXX XXX XXX XXX XXX
Healius XXX XXX XXX XXX XXX XXX
Integral Diagnostics XXX XXX XXX XXX XXX XXX
Sonic Healthcare XXX XXX XXX XXX XXX XXX
Bangkok Dusit Medical Services XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Revvity M&A and Investment Activity

Revvity acquired  XXX companies to date.

Last acquisition by Revvity was  XXXXXXXX, XXXXX XXXXX XXXXXX . Revvity acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Revvity

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Revvity

When was Revvity founded? Revvity was founded in 1947.
Where is Revvity headquartered? Revvity is headquartered in United States of America.
How many employees does Revvity have? As of today, Revvity has 11K+ employees.
Who is the CEO of Revvity? Revvity's CEO is Dr. Prahlad R. Singh, PhD.
Is Revvity publicy listed? Yes, Revvity is a public company listed on NYS.
What is the stock symbol of Revvity? Revvity trades under RVTY ticker.
When did Revvity go public? Revvity went public in 1983.
Who are competitors of Revvity? Similar companies to Revvity include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare.
What is the current market cap of Revvity? Revvity's current market cap is $11.7B
What is the current revenue of Revvity? Revvity's last 12-month revenue is $2.8B.
What is the current EBITDA of Revvity? Revvity's last 12-month EBITDA is $862M.
What is the current EV/Revenue multiple of Revvity? Current revenue multiple of Revvity is 5.0x.
What is the current EV/EBITDA multiple of Revvity? Current EBITDA multiple of Revvity is 16.1x.
What is the current revenue growth of Revvity? Revvity revenue growth between 2023 and 2024 was 0%.
Is Revvity profitable? Yes, Revvity is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.